Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $54.90, for a total value of $1,647,000.00. Following the transaction, the chief executive officer now directly owns 716,062 shares in the company, valued at $39,311,803.80. This trade represents a 4.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Andrew Cheng also recently made the following trade(s):

• On Tuesday, December 10th, Andrew Cheng sold 7,855 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total value of $241,855.45.
• On Monday, December 2nd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.09, for a total transaction of $802,250.00.
• On Friday, November 1st, Andrew Cheng sold 108,366 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.73, for a total transaction of $3,438,453.18.

Akero Therapeutics Stock Performance

Shares of AKRO stock opened at $54.00 on Thursday. The company has a market capitalization of $3.77 billion, a P/E ratio of -14.40 and a beta of -0.19. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The company’s 50 day moving average price is $29.31 and its two-hundred day moving average price is $28.51.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, analysts expect that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AKRO. abrdn plc boosted its position in Akero Therapeutics by 118.7% during the 4th quarter. abrdn plc now owns 269,782 shares of the company’s stock worth $7,505,000 after acquiring an additional 146,424 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Akero Therapeutics by 10.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company’s stock worth $412,000 after purchasing an additional 1,446 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Akero Therapeutics by 4,022.1% during the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after purchasing an additional 583,486 shares during the last quarter. Exome Asset Management LLC bought a new position in Akero Therapeutics in the third quarter valued at $2,212,000. Finally, Barclays PLC increased its stake in Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock valued at $3,662,000 after buying an additional 71,652 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on AKRO shares. Morgan Stanley increased their price target on Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research note on Tuesday. HC Wainwright boosted their target price on Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday. Canaccord Genuity Group upped their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Citigroup lifted their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $61.57.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.